Piroxicam beta cyclodextrin

β-CD is a simple compound composed of seven glucose molecules with an inner diameter of 0.7-0.8 nm. As a result, some or all of the drug molecules may enter the simple structure of β-CD to form an inclusion compound, thereby altering certain properties of the drug. For non-steroidal anti-inflammatory drugs, this may reduce gastrointestinal irritation.

Piroxicam is a new non-steroidal anti-inflammatory drug with notable analgesic, anti-inflammatory, and anti-swelling effects. It requires a small dosage, has a long half-life, lacks an accumulation effect, and has a definite therapeutic effect. However, due to its poor water solubility and slow absorption, oral administration can lead to gastrointestinal bleeding.

Piroxicam-β-Cyclodextrin utilizes a unique process to encapsulate pharmaceutical-grade piroxicam with pharmaceutical-grade beta-cyclodextrin at a specific ratio. This refined inclusion compound has a lower odor, greater stability, and a smoother drug release rate compared to piroxicam monomer. Piroxicam-β-Cyclodextrin is mainly used in anti-inflammatory analgesics and as a pharmaceutical excipient.

When piroxicam is prepared as a cyclodextrin inclusion compound, the drug's dissolution rate is accelerated, and gastrointestinal irritation is reduced.